Noom Launches OpenRx, Selling Compounded Sermorelin, NAD+, and Oxytocin Tablets and Reviewing BPC-157 and TB-500
Noom launched OpenRx on November 17 as a separate brand for clinician-prescribed peptide and preventive treatments, filled through its 503A compounding pharmacy network. It starts with injectable sermorelin and NAD+, a dissolvable tablet that combines PT-141, oxytocin, and tadalafil for sexual health, and an oxytocin-only tablet. Chief medical officer Dr. Jeffrey Egler said the company is reviewing BPC-157 and TB-500. The release promises "transparent pricing" but lists no prices.